Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 4;117(49):843-854.
doi: 10.3238/arztebl.2020.0843.

Current Treatment for Benign Prostatic Hyperplasia

Arkadiusz Miernik  1 , Christian Gratzke
Affiliations
Review

Current Treatment for Benign Prostatic Hyperplasia

Arkadiusz Miernik et al. Dtsch Arztebl Int. .

Abstract

Background: Benign prostatic hyperplasia (BPH) is characterized by the occurrence of.disorders of urine storage and bladder emptying. Most men over the age of 60 years are affected to some degree.

Methods: A selective literature search with additional scrutiny of guidelines and meta-analyses.

Results: The management of patients with BPH is complex. Emptying and retention disorders can be treated by various pharmacological and surgical means. Transurethral resection of the prostate (TURP) has long been considered the gold standard for operative treatment. Transurethral enucleation procedures show a better risk profile in some uses, however, and have, above all, largely displaced suprapubic prostatectomy. Numerous innovative treatment options have been developed in recent years, but their long-term effects remain to be determined. These treatment techniques can nevertheless be used in individual cases after thorough discussion with the patient.

Conclusion: The care of patients with BPH should be interdisciplinary. The efficacy and safety of many new developments in the area of pharmacological and minimally invasive treatment remain to be demonstrated in randomized trials.

PubMed Disclaimer

Figures

Figure
Figure
Flow chart for recommendation medical management of patients with possibly BPH-related symptoms, based on the guidelines of the European Society of Urology [recommended scope of follow-up: history, IPSS, ICIQ, IIEF, urinalysis, physical examination (including DRE), PSA, urinary tract ultrasonography as appropriate] (1) BPH, benign prostatic hyperplasia; DRE, digital rectal examination; HoLEP, holmium laser enucleation of the prostate; ICIQ, International Consultation on Incontinence Questionnaire; IIEF, International Index of Erectile Function; IPSS, International Prostate Symptom Score; PSA, prostate-specific antigen; PVR, postvoid residual urine; TUIP, transurethral incision of the prostate; ThuLEP, thulium laser enucleation; TURP, bipolar transurethral prostateresection
See this image and copyright information in PMC

References

    1. Gravas S, Cornu J, Gacci M, et al. EAU Guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl benign prostatic obstruction (BPO) 2019. European Association of Urology 2019. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ (last accesssed on 19 September 2019)
    1. Barry MJ, Fowler FJ Jr, O‘Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–1564. - PubMed
    1. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43:289–297. - PubMed
    1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–479. - PubMed
    1. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22:1–6. - PubMed